ODM 201

Drug Profile

ODM 201

Alternative Names: BAY 1841788; ODM-201

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Orion
  • Developer Bayer HealthCare; Orion
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 22 Dec 2016 Translational Research in Oncology and Bayer plan a phase 0 trial in Breast cancer in USA, Canada and Germany (NCT03004534)
  • 21 Nov 2016 European Organisation for Research and Treatment of Cancer plans a phase II trial for Prostate cancer in Belgium, Italy, Spain and Austria (PO) (NCT02972060)
  • 13 Oct 2016 Swiss Group for Clinical Cancer Research plans a phase II trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Switzerland (PO) (NCT02933801)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top